Table 3.

Univariate and multivariate models for progression free survival and overall survival in patients with metastatic triple negative breast cancer

		Univariate						Multivariate
		Progression Free			Overall			Progression Free			Overall
Factor	No.	Median(months)	95% CI	P	Median (months)	95% CI	P	HR	95% CI	P	HR	95%CI	P
Age				.59			.61
≤ 40	12	3.8	2.5 to 5.0		13.1	-
> 40	32	4.3	4.1 to 4.4		12.6	7.3 to 17.8
Menopausal status				.91			.59
Pre- or perimenopause	20	3.8	2.2 to 5.3		12.6	7.3 to 17.8
Postmenopause	24	4.3	4.1 to 4.5		14.2	4.3 to 24.1
Interval＊				.03			<.001						<.001
≤ 1 year	17	2.2	0.8 to 3.5		5.9	3.2 to 8.6					5.45	2.08 to 14.32
> 1 year	27	4.6	4.1 to 5.0		14.2	14.0 to 14.5
Visceral involvement				.71			.20
No	10	4.4	4.0 to 4.8		Not reached
Yes	34	4.1	3.2 to 5.1		10.0	3.4 to 16.7
No. of metastatic sites				.62			.18
1	9	4.6	3.3 to 5.8		14.1	12.2 to 16.1
2	18	4.3	0.0 to 8.6		9.4	4.5 to 14.3
≥ 3	17	4.2	1.5 to 7.0		12.6	8.1 to 17.0
Cis/carbo-platin pretreated for MBC				.11			.14
Yes	25	2.2	1.6 to 2.8		10.0	3.1 to 16.9
No	19	4.5	4.1 to 5.0		Not reached
TTP of 1–2 previous regimens before recruitment ≤ 3 month				<.001			<.001			<.001
Yes	17	2.1	1.7 to 2.5		4.0	1.5 to 6.5		3.39	1.66 to 6.89
No	27	4.7	2.0 to 7.4		14.2	12.4 to 16.1

^＊Interval from diagnosis of breast cancer to recurrence